April 18th 2025
The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Kite Collaborates with UCLA to Develop Off-The-Shelf Allogenic T-Cell Therapies
July 26th 2016On July 25, 2016 Kite Pharma entered into an agreement with the University of California, Los Angeles, (UCLA) to advance development of off-the-shelf allogenic T-cell therapies from renewable pluripotent stem cells. The company entered into an exclusive license agreement with UCLA for an artificial thymic organoid (ATO) cell culture system. The ATO replicates the human thymic environment to support efficient ex vivo differentiation of T-cells from primary and reprogrammed pluripotent stem cells.